Lanatoside C is primarily used in the pharmaceutical industry for the treatment of heart-related conditions, particularly congestive heart failure and certain cardiac arrhythmias. It functions by inhibiting the Na⁺/K⁺-ATPase pump in cardiac muscle cells, which leads to increased intracellular sodium and calcium levels. This mechanism enhances myocardial contractility, resulting in improved cardiac output. It is also used to control ventricular rate in patients with atrial fibrillation due to its effects on cardiac conduction, particularly by increasing vagal tone and slowing AV node conduction. Due to its narrow therapeutic index, Lanatoside C requires careful dosing and monitoring. It is typically administered in hospital or clinical settings where cardiac function can be closely observed. Its use has declined somewhat with the advent of newer cardiac medications, but it remains an option in specific acute or refractory cases.